期刊文献+

淋巴毒素β受体和核转录因子-κB经典通路P65在膀胱组织中表达的实验研究 被引量:3

An experimental research on effect of LTI3R and P65 in progression of bladder cancer
原文传递
导出
摘要 目的探讨淋巴毒素β受体(LTβR)和核转录因子(NF)-κB经典通路因子P65在膀胱癌(BCa)和膀胱炎组织中的表达情况及与BCa临床病理指征的关系。方法采用实时荧光定量PcR检测108份新鲜膀胱组织标本(按照病理检查结果分为BCa组75份、膀胱炎组10份和正常膀胱黏膜组23份)中的LT[3R和P65的mRNA相对含量;采用免疫组织化学方法检测118份病理石蜡切片(BCa切片组73份、膀胱炎切片组30份和正常膀胱黏膜切片组15份)中的LTβR与磷酸化蛋白P65(p-P65)表达水平,并分析其表达与BCa分级分期和淋巴结转移等因素的关系。采用Kruskal-Wallis H验和χ2检验等比较不同膀胱组织间的LTBR与P65的mRNA和蛋白表达水平。结果(1)LTβR和P65mRNA相对含量在膀胱癌组中高于正常组[LTβR:29.4(14.2~46.7)×10-3、1.2(0.3~7.0)×10-3,Z=-5.508;P65:9.7(2.7~21.1)×10-3、1.0(0.8~1.8)×10-3,Z=-5.030,P均〈0.05],两者在BCa进展[病理分级各组(Ⅰ、Ⅱ、Ⅲ级):LTBR:18.2(2.1~31.3)×10-3、28.4(16.6—36.2)×10-3、47.9(34.3~70.5)×10-3,χ2K-W=20.378;P65:4.9(1.3—12.0)×10-3、7.4(3.0~21.9)×10-3、17.0(10.0~28.3)×10-3,χ2K-W=15.219,P均〈0.05]和淋巴结转移各组(阴性、阳性)[LTβR:27.2(9.7~40.1)×10-3、39.4(26.7—52.6)×10-3,Z=-2.552;P65:7.4(2.3~15.6)×10-3、13.4(6.7~23.3)×10-3,Z=-2.026,P均〈0.05]比较差异均有统计学意义。(2)IJTpR和p-P65蛋白阳性率在膀胱癌组中高于正常组(LTpR:69.8%、13.3%,χ2=16.600;P65:56.2%、6.7%,χ2=12.220,P均〈0.05)。LTBR和p-P65蛋白阳性率也在BCa进展(病理分级各组(Ⅰ、Ⅱ、Ⅲ级):LTBR:56.3%、70.0%、90.4%,χ2=7.055;p-P65:40.6%、60.0%、76.2%,χ2=6.679,P均〈0.05)和淋巴结转移各组(阴性、阳性)(L113R:58.3%、92.0%,χ2=8.849;p-P65:52.1%、64.0%,χ2=5.088,P均〈0.05)比较差异均有统计学意义。(3)相关性分析显示,LTBR与P65的表达在膀胱癌组中呈正相关(mRNA:r=0.654,P〈0.05;蛋白:r=0.399,P〈0.05),LTpR与P65蛋白表达在膀胱炎组中呈正相关(r=0.521,P〈0.05)。结论LTpR和P65在膀胱癌组织中高表达,LTBR的表达可能与膀胱癌的发生发展和转移有关,且LTβR可能通过P65的激活参与经典的NF—κB通路。 Objective To investigate the relationship of lymphotoxin β receptor (LTβR) and classical nuclear faetor-κB (NF-κB) activation pathway in the pathogenesis and progress of cystitis and bladder cancer. Methods The LTβR and P65 mRNA expression were detected by Real-time quantitative PCR in 108 cases of fresh bladder tissue specimens (75 cases of bladder cancer, 10 cases of inflammation and 23 normal bladder mucosa cases grouped by the tissue classification), and protein expression were analyzed by immunohistochemistry assay in 118 cases of paraffin-embedded biopsy specimens (73 cases of bladder cancer, 30 cases of cysitis and 15 normal bladder mucosa cases). The correlation analysis between the expressions of LTI3R and P65 with clinical pathological data was then performed. Differences between LTI3R and P65 mRNA and protein expression level were compared in different groups of bladder tissues using Kruskal-WaUis H test and the Chi-square test. Results (1)The mRNA expressions of LTI3R and NF-KB/P65 were higher in bladder cancer than those in normal group (LTβR:29.4 ( 14. 2 -46. 7 ) ×10-3/1.2 (0. 3 - 7.0) ×10-3, Z= -5.508; P65:9.7 (2.7 -21.1)×10-3/1.0(0. 8 - 1.8) ×10-3, Z= -5.030, P〈 0.05 ). There were significantly differences between bladder cancer with different histological grades ( LTβR : 18.2(2.1-31.3) ×10-3/ 28.4(16.6- 36.2)×10-3/47.9(34. 3 - 70.5) ×10-3, A/K-W2 = 20. 378 ; p- P65:4.9(1.3-12.0) ×10-3/7.4(3.0-21.9) ×10-3/17.0(10.0-28.3) ×10-3 2 =15.219, Pall χ2K-W 〈0. 05) and lymph node metastasis (LTβR:27.2(9.7 -40. 1 ) ×10-3/39. 4(26. 7 -52. 6) ×10-3, Z = -2.552; P65:7.4(2.3-15.6) ×10-3/13.4(6.7-23.3)×10-3, Z= -2.026, P 〈0.05). (2)The positive rates of LTβR and phosphorylated P65 (p-P65) protein in cancer were higher than those of normal group ( LTβR : 69.8 % / 13.3 %, χ2 = 16. 600 ; p-P65 : 56. 2 %/6. 7 % , X2 = 12. 220, P 〈 0. 05 ). Upregulation of LTβR and p-P65 were associated with the histological grade (LTf3R: 56. 3%/70. 0%/90.4%, χ2 = 7.055 ; p-P65:40. 6%/60. 0%/76. 2%, X: = 6. 679, P 〈 0. 05 ) and with lymph node metastasis ( LTβR: 58.3 %/92. 0%, X2 = 8. 849 ; p-P65:52. 1% / 64. 0%, χ2= 5. 088, P 〈 0. 05 ). ( 3 ) There was a positive correlation between LTβR and P65 expression (mRNA-r =0. 654, P 〈0. 05, protein-r =0. 399, P 〈0.05) in the bladder cancer and cystitis (r = 0. 521, P 〈 0. 05). Conclusions The activation of LTf3R and P65 was associated with progression and metastasis of bladder cancer. The activation of classical NF-κB pathway by LTβR may be achieved by P65.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2012年第5期436-442,共7页 Chinese Journal of Laboratory Medicine
基金 浙江省自然科学基金资助项目(Y2110555)
关键词 膀胱肿瘤 膀胱炎 淋巴毒素β受体 转录因子RelA Urinary bladder neoplasms Cystitis Lymphotoxin beta receptor Transcription factor RelA
  • 相关文献

参考文献19

  • 1Society AC. Cancer facts & figures 2011. Atlanta: American Cancer Society, 2011.
  • 2张思维,马建辉,李鸣,那彦群,陈万青.中国部分市县膀胱癌发病趋势比较研究[J].中华泌尿外科杂志,2009,30(10):673-676. 被引量:42
  • 3Michaud DS. Chronic inflammation and bladder cancer. Urol Oncol, 2007, 25:260-268.
  • 4赵纪宇,陈立军.膀胱癌免疫治疗研究进展[J].军事医学科学院院刊,2009,33(4):395-397. 被引量:1
  • 5Ammirante M, Luo JL, Grivennikov S, et al. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature, 2010, 464:302-305.
  • 6Haybaeck J, Zeller N, Wolf M J, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell, 2009,16:295-308.
  • 7Lukashev M, LePage D, Wilson C, et al. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res, 2006, 66:9617-9624.
  • 8Zhou P, Fang X, McNally BA, et al. Targeting lymphotoxin- mediated negative selection to prevent prostate cancer in mice with genetic predisposition. Proc Natl Acad Sci U S A, 2009, 106: 17134-17139.
  • 9Browning JL. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev, 2008, 223:202-220.
  • 10Dobrovolskaia MA, Kozlov SV. Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership. Curt Cancer Drug Targets, 2005, 5:325-344.

二级参考文献17

  • 1WANGJian,LIUXin-guang,HECheng-wei,HEHui-juan,WUping,HUANGPing-ping,CHENXiao-wen,DONGZhong,WUXiu-dong,LINLi-guo,LIUJian-jun.Synergic anti-tumour effect of B7.1 gene modified tumour vaccine combined with allicin for murine bladder tumour[J].Chinese Medical Journal,2005(3):242-245. 被引量:5
  • 2张思维,陈万青,孔灵芝,李连弟,鲁凤珠,李光琳,孟佳,赵平.中国部分市县1998~2002年恶性肿瘤的发病与死亡[J].中国肿瘤,2006,15(7):430-448. 被引量:171
  • 3卢炳新,韩瑞发,汤洋,韩育植,李盛芝.应用重组分泌型内皮抑素腺相关病毒治疗膀胱癌的实验研究[J].中华医学杂志,2007,87(12):802-805. 被引量:3
  • 4Jensen OM, Parkin DM, MacLennan R, et al. Cancer registration: principles and methods. IARC Scientific Publication No. 95. Lyon: IARC, 1991:101- 107.
  • 5Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC Technical Report No. 19. Lyon: IARC, 1994: 35-49.
  • 6Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC Technical Report No. 42. Lyon: IARC, 2005: 11-38.
  • 7Felay J. The IARCcrgTools program, http://www, iacr. com. fr/ iarccrgtools, htm. IACR. Lyon. 2006.
  • 8李连弟,饶克勤.中国试点市县恶性肿瘤的发病与死亡:第1卷(1988-1992).北京:中国医药科技出版社,2002:263-289.
  • 9李连弟,饶克勤.中国试点市县恶性肿瘤的发病与死亡:第2卷(1993-1997).北京:中国医药科技出版社,2003:269-295.
  • 10李连弟,饶克勤,孔灵芝,等.中国试点市县恶性肿瘤的发病与死亡:第3卷(1999-2002).北京:人民卫生出版社,2007:314-316.

共引文献226

同被引文献9

  • 1Aggarwal B, Vijayalekshmi R, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short - term friend, long - term foe [ J ]. Clin Cancer Res, 2009, 15 (2) : 425 - 430.
  • 2Michaud D. Chronic inflammation and bladder cancer [ J ]. Urol Oncol, 2007, 25 (3) : 260 - 268.
  • 3Qiao L, Zhang H, Yu J, et al. Constitutive activation of NF -kap- paB in human hepatocellular carcinoma: evidence of a cytoprotec- tire role[J]. Hum Gene Ther, 2006, 17(3) : 280 -290.
  • 4Sub J, Rabson A. NF -kappaB activation in human prostate canc- er: important mediator or epiphenomenon? [ J]. J Cell Biochem, 2004, 91(1): 100-117.
  • 5Shen M, Duan X, Zhou P, et al. Lymphotoxin 13 receptor activa- ting nuclear factor - KB pathwaypromotes bladder cancer [ J ]. Molecu Med Rep, 2015, 11 (2): 783 -790.
  • 6Karin M. NF- kappaB as a critical link between inflammation and cancer [ J]. Cold Spring Harb Perspect Biol, 2009, 1 (5) : a000141.
  • 7Sethi G, Sung B, Aggarwal B. TNF : a master switch for inflamma- tion to cancer [ J]. Front Biosci, 2008, 13 ( 13 ) : 5094 - 5 107.
  • 8陆福鼎,许可慰,毕良宽,刘成,玄绪军,黄海.C型凝集素样受体1在卡介苗灌注治疗膀胱癌中的作用及机制[J].中华实验外科杂志,2014,31(5):1069-1071. 被引量:2
  • 9高胜利,徐亮亮,庞作良.TLR4与NF-κB蛋白在非小细胞肺癌组织中的表达及临床意义[J].实用临床医药杂志,2014,18(9):68-71. 被引量:2

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部